CD8+细胞中mTOR激活参与类风湿关节炎疾病活动性并提高TNF抑制剂的治疗反应
本研究从17名健康对照和86例RA患者外周血分离PBMC,评估CD8+细胞p-mTOR水平与临床相关性及体外作用。RA患者CD8+细胞p-mTOR水平高于健康对照且与疾病活动度正相关;TNF抑制剂治疗一年后p-mTOR被抑制并与治疗反应正相关,阿巴西普组未见此现象。结论提示CD8+细胞mTOR激活可能是RA疾病活动性的新评估标志物及TNF抑制剂治疗反应的预测标志物。
要点
- RA患者CD8+细胞p-mTOR水平高于健康对照,且与疾病活动度正相关。
- TNF抑制剂治疗一年后CD8+细胞p-mTOR被抑制并与治疗反应正相关,阿巴西普组未见。
- 体外抗CD3/抗CD28刺激诱导CD8+细胞mTOR磷酸化并改变颗粒酶B、颗粒溶素、TNF-α、IFN-γ和颗粒酶K产生。
核心结论
- 结果提示CD8+细胞中mTOR激活可能是RA疾病活动性的新评估标志物及TNF抑制剂治疗反应的预测标志物。
研究设计与样本
- 从17名健康对照和86例RA患者分离外周血单个核细胞(PBMC),评估mTOR磷酸化(p-mTOR)及其临床相关性,并在体外检查mTOR在CD8+细胞中的作用。
主要发现
- RA患者CD8+细胞p-mTOR水平高于健康对照,且与患者疾病活动度正相关。
- TNF抑制剂治疗一年后CD8+细胞p-mTOR水平被抑制并与治疗反应正相关,阿巴西普治疗组未观察到这一现象。
- 体外抗CD3和抗CD28抗体刺激CD8+细胞诱导mTOR磷酸化,并增加颗粒酶B、颗粒溶素、TNF-α和IFN-γ产生,但减少颗粒酶K产生。
- TNF抑制剂处理后CD8+细胞p-mTOR水平和颗粒酶B产生减少,而颗粒酶K产生增加;颗粒溶素和IFN-γ产生未受TNF抑制剂影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to understand the role of mammalian target of rapamycin (mTOR) in CD8+ cells in the pathogenicity of RA and the changes after treatment with biologic drugs. METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from 17 healthy controls and 86 patients with RA. Phosphorylation of mTOR (p-mTOR) and its clinical relevance were evaluated. The role of mTOR in CD8+ cells was also examined in vitro. RESULTS: Patients with RA who had a moderate or high disease activity, were biologic-naïve, and were refractory to MTX were enrolled in this study. The p-mTOR levels in CD8+ cells were higher in patients with RA than in healthy controls, and they positively correlated with the disease activity in such patients. However, after one year of treatment with TNF inhibitors, the p-mTOR levels in CD8+ cells were suppressed and showed a positive correlation with the treatment response, which was not observed in the abatacept-treatment group. In vitro stimulation of CD8+ cells with anti-CD3 and anti-CD28 antibodies induced mTOR phosphorylation and increased the production of granzyme B, granulysin, TNF-α and IFN-γ but decreased the production of granzyme K. However, on treatment with TNF inhibitors, p-mTOR levels in CD8+ cells and granzyme B production decreased, while granzyme K production increased. The production of granulysin and IFN-γ was not affected by the TNF inhibitors. CONCLUSION: These results suggested that mTOR activation in CD8+ cells may be a novel evaluation marker for RA disease activity and a predictive marker of therapeutic response to TNF inhibitors.
引用
- Zhang M, Iwata S, Sonomoto K, et al. mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology (Oxford). 2022. PMID: 34791054. doi:10.1093/rheumatology/keab834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。